Eli Lilly | LLY - Cash And Equivalent


Eli Lilly reported $8.95B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Abbott USD 6.8B 1.72B Mar/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Drreddys Laboratories INR 15.37B 3.29B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Medtronic USD 1.95B 802M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Perrigo USD 357.2M 174.4M Mar/2026
Pfizer USD 976M 727M Jun/2026
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 89.13M 25.26M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sanofi EUR 5.54B 2.11B Mar/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Zoetis USD 1.48B 465M Jun/2026